Similar effects have been observed in solid tumor trials where anti–CTLA-4 has been combined with anti–PD-1, resulting in a widened immune repertoire and reactivation of the putative tumor-reactive, terminally differentiated memory T cells with clinical benefit (66). This evidence concerns the gene CTLA4 and neoplasm.